
Luke Kuttschreuter
Clinical Lead, Early Development Oncology
Poster
INVOKE: a Phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.
Date
June 2, 2025
Time
1:30 pm
Abstract
TPS2683
Poster number
322b